Vijeeth Guggilla

Vijeeth Guggilla

Auto-generated profile, based on publicly available information

Vijeeth Guggilla

Northwestern University Feinberg School of Medicine

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 September 2025 in Journal of the American Medical Informatics Association
Verified
Journal Article
Open access
VGVijeeth Guggilla
Vijeeth Guggilla
MKMengjia Kang
Mengjia Kang
MBMelissa J Bak
Melissa J Bak
STSteven D Tran
Steven D Tran
APAnna Pawlowski
Anna Pawlowski
NINU SCRIPT Study Investigators
NU SCRIPT Study Investigators
Objective: Rule-based structured data algorithms and natural language processing (NLP) approaches applied to unstructured clinical notes have limited accuracy and poor generalizability for identifying immunosuppression. Large language models (LLMs) may effectively identify patients with heterogenous types of immunosuppression from unstructured clinical notes. We compared the performance of LLMs applied to unstructured notes for identifying patients with immunosuppressive conditions or immunosuppressive medication use against 2 baselines: (1) structured data algorithms using diagnosis codes and medication orders and (2) NLP approaches applied to unstructured notes. Materials and Methods: We used hospital admission notes from a primary cohort of 827 intensive care unit (ICU) patients at Northwestern Memorial Hospital and a validation cohort of 200 ICU patients at Beth Israel Deaconess Medical Center, along with diagnosis codes and medication orders from the primary cohort. We evaluated the performance of structured data algorithms, NLP approaches, and LLMs in identifying 7 immunosuppressive conditions and 6 immunosuppressive medications. Results: In the primary cohort, structured data algorithms achieved peak F1 scores ranging from 0.30 to 0.97 for identifying immunosuppressive conditions and medications. NLP approaches achieved peak F1 scores ranging from 0 to 1. GPT-4o outperformed or matched structured data algorithms and NLP approaches across all conditions and medications, with F1 scores ranging from 0.51 to 1. GPT-4o also performed impressively in our validation cohort (F1 = 1 for 8/13 variables). Discussion: LLMs, particularly GPT-4o, outperformed structured data algorithms and NLP approaches in identifying immunosuppressive conditions and medications with robust external validation. Conclusion: LLMs can be applied for improved cohort identification for research purposes.

8 August 2025 in PLOS ONE
Verified
Journal Article
Open access
VGVijeeth Guggilla
Vijeeth Guggilla
JPJennifer A. Pacheco
Jennifer A. Pacheco
ACAlexandre M. Carvalho
Alexandre M. Carvalho
GWGrant R. Whitmer
Grant R. Whitmer
APAnna E. Pawlowski
Anna E. Pawlowski
TWTheresa L. Walunas
Theresa L. Walunas
Background: Adults with immunosuppression are more likely to develop severe COVID-19 than adults without immunosuppression. Less is known about differences in outcomes for adults with immunosuppression who are hospitalized with COVID-19. Methods: A retrospective cohort study of adults hospitalized with COVID-19 at Northwestern Medicine hospitals between 03/01/2020 and 05/31/2022 was performed. Regression analyses were performed comparing in-hospital mortality, intensive care unit (ICU) admission, oxygenation requirements, and hospital/ICU length of stay among patients without immunosuppression (n = 9079) and patients with immunosuppression (n = 873). Results: Patients with immunosuppression had significantly higher mortality than patients without immunosuppression (OR: 1.33, 95% CI: 1.11–1.60). This effect was even stronger when controlling for age at admission, diabetes, obesity, SARS-CoV-2 variant era, and COVID-19 medication use (adjusted OR: 1.78, 95% CI: 1.46–2.16). ICU admission (adjusted OR: 1.64, 95% CI: 1.41–1.90) and invasive ventilation (adjusted OR: 1.68, 95% CI: 1.36–2.06) were also significantly higher in patients with immunosuppression. Hospitalization length (median: 7 days) and ICU length of stay (median: 2.5 days) were longer in patients with immunosuppression compared to patients without immunosuppression (median: 5 days, adjusted p < 0.001; median: 2 days, adjusted p = 0.04). Subgroup analyses showed that patients with solid organ transplant, HIV with low CD4 cell count, and secondary immunodeficiency had significantly higher adjusted mortality and ICU admission compared to patients without immunosuppression. Patients with solid organ transplant also had significantly higher invasive ventilation and ICU length of stay. Conclusions: Patients with immunosuppression had worse outcomes than patients without immunosuppression. Subgroup analyses showed that patients with solid organ transplant had the worst outcomes overall. Patients with HIV had similar outcomes as patients without immunosuppression unless CD4 cell count was low.

17 January 2025 in medRxiv
Verified
Preprint
Open access
PDF file
VGVijeeth Guggilla
Vijeeth Guggilla
MKMengjia Kang
Mengjia Kang
MBMelissa J Bak
Melissa J Bak
STSteven D Tran
Steven D Tran
APAnna Pawlowski
Anna Pawlowski
TIThe NU SCRIPT Study Investigators
The NU SCRIPT Study Investigators
Identifying immunosuppressed patients using structured data can be challenging. Large language models effectively extract structured concepts from unstructured clinical text. Here we show that GPT-4o outperforms traditional approaches in identifying immunosuppressive conditions and medication use by processing hospital admission notes. We also demonstrate the extensibility of our approach in an external dataset. Cost-effective models like GPT-4o mini and Llama 3.1 also perform well, but not as well as GPT-4o.

14 May 2026 in bioRxiv
Verified
Preprint
Open access
NMNikolay S Markov
Nikolay S Markov
MMMarcin Możejko
Marcin Możejko
VGVijeeth Guggilla
Vijeeth Guggilla
MŁMałgorzata Łazęcka
Małgorzata Łazęcka
HDHelen K Donnelly
Helen K Donnelly
ESEwa Szczurek
Ewa Szczurek
Pneumonia is the leading cause of death from infectious disease worldwide. The diagnosis and treatment of patients with pneumonia lag behind other major conditions, relying on syndromic definitions that lack molecular resolution and ignore underlying endotypes. We sought to test the hypothesis that dynamic pathogen-specific host responses in the alveolar space represent distinct pneumonia endotypes linked to different clinical features and outcomes. We prospectively enrolled a cohort of 690 patients (including immunocompromised patients) with known or suspected pneumonia receiving mechanical ventilation in whom the etiology of pneumonia was determined by gold-standard analysis of distal lung fluid obtained by bronchoalveolar lavage (BAL) combined with clinical adjudication. From these patients, we analyzed 792 BAL fluid samples, including 310 serial samples, using flow cytometry (482 patients) and single-cell RNA-sequencing (170 patients; 263 samples, complemented by 9 healthy controls and 25 post-COVID-19 patients, yielding ~2.4 million single cells across 28 cell types), and extracted daily clinical data from the electronic health record (>15,000 patient-days). We used machine learning models to identify pathogen-specific host responses in the transcriptome of alveolar immune cells that were associated with changes in alveolar cell abundance and clinical features. Our results suggest that therapeutic strategies for pneumonia should be individualized to specific host-pathogen interactions.

6 November 2025 in medRxiv
Verified
Preprint
Open access
PDF file
VGVijeeth Guggilla
Vijeeth Guggilla
CPChiagozie Pickens
Chiagozie Pickens
HDHelen K Donnelly
Helen K Donnelly
APAnna Pawlowski
Anna Pawlowski
EKErin Korth
Erin Korth
TIThe NU SCRIPT Study Investigators
The NU SCRIPT Study Investigators
Background: Despite sophisticated standard of care (SOC) testing (including bronchoalveolar lavage (BAL) fluid culture and multiplex PCR), the etiology of pneumonia in immunocompromised patients is frequently unknown. Microbial cell-free DNA (mcfDNA) sequencing increases diagnostic yield in plasma but remains understudied in BAL fluid. Methods: This was a single center, retrospective, observational cohort study. Residual BAL fluid collected from immunocompromised, mechanically ventilated patients with suspected pneumonia was sent to Karius® for mcfDNA sequencing. Given the retrospective design, mcfDNA sequencing results were unavailable to clinicians. SOC testing results were compared to Karius® BAL (KT-BAL) test reports that classified identified microorganisms as Category One (always pathogenic), Category Two (usually pathogenic), or Category Three (rarely pathogenic). Findings: 228 BAL fluid samples from 155 patients were analyzed. In pneumonia patients, KT-BAL yielded 18 additional Category One organisms, 138 additional Category Two organisms, and 313 additional Category Three organisms compared to SOC. Organisms missed by SOC and identified by KT-BAL included bacterial pathogens (99 patients), clinically relevant DNA viruses (34 patients), non- Candida fungi (11 patients), and parasites (1 patient). Compared to patients with Category One or Two organisms identified by both SOC and KT-BAL (n = 68), patients with organisms identified by KT-BAL alone (n = 87) had significantly more cumulative intubation days (11 [5, 20] days vs. 15 [8, 32] days, p = 0.035). Interpretation: KT-BAL increased diagnostic yield for immunocompromised patients with suspected pneumonia with suggestion of prolonged respiratory failure in patients with pathogens missed by SOC.

30 May 2026 in medRxiv
Verified
Preprint
Open access
PDF file
SCS. Marina Casalino-Matsuda
S. Marina Casalino-Matsuda
VGVijeeth Guggilla
Vijeeth Guggilla
CGCatherine A Gao
Catherine A Gao
KDKaitlyn E Demeulenaere
Kaitlyn E Demeulenaere
LCLuisa P Cusick
Luisa P Cusick
GBG.R. Scott Budinger
G.R. Scott Budinger
Viral pneumonia is perpetuated by inflammatory circuits between activated T cells and monocyte-derived alveolar macrophages (MoAM). T cells and macrophages express ORAI1 and STIM1, which form calcium release-activated calcium (CRAC) channels that allow extracellular calcium entry in response to endoplasmic reticulum calcium store depletion. In a randomized, placebo-controlled, multicenter phase 2 trial (CARDEA), Auxora, a CRAC channel inhibitor, reduced all-cause 30-day mortality by 56% in patients with severe SARS-CoV-2 pneumonia. Here, we report a multi-omics analysis of serially collected alveolar samples from unvaccinated patients with severe SARS-CoV-2 pneumonia treated with Auxora versus placebo. We found reductions in plasma levels of the monocyte– and T cell-chemokines, CCL8 and PDGF-AA. Using peripheral blood mononuclear cells (PBMC) from healthy volunteers, we show that Auxora directly targets T cells to inhibit the transcription of CCL8 and PDGFA in monocyte-derived macrophages, supporting a mechanism for its effects and a potential intermediate biomarker of efficacy.